Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPYTTOLE: Caelyx and Docetaxel in Metastatic Breast Cancer
NCT00524810Phase 2Completed
- Sponsor
- ARCAGY
- Start
- Feb 2004
- Primary completion
- Jun 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin and docetaxel in breast cancer, sponsored by ARCAGY. Primary endpoint: Non-progression rate after 6 cycles at 6 months. Started Feb 2004; status: completed.
02
Drugs
doxorubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00524810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00524810.